The ISPE Chesapeake Bay Area Chapter Mid-Atlantic Science & Technology (MAST) Virtual Showcase, hosted on May 19th, 2021, provided a platform for life science companies to discuss strategies for addressing challenges in the life science industry.
With the availability of academic positions on the decline, and a boom in startups resulting from disruptive technologies, some PhDs are looking to utilize their unique set of skills in a slightly nontraditional way – venture capitalism (VC). One VC firm, called Fifty Years, has recently concluded its inaugural program (PhD to VC), which aimed at preparing young scientists with the skills needed to jumpstart their VC careers.
Improving access to venture capital for life science entrepreneurs and emerging biopharma companies in the BioHealth Capital Region (BHCR) is a top priority. However, elevating the region’s funding profile is not the only type of access undergoing a transformation in recent years.
Paul Nolde has close to two decades of experience in the banking, finance, and venture capital sectors, serving in multiple business development and management roles. As the Fund Manager and Managing Director of Riverflow Growth Fund, a seed-stage venture capital fund based in Richmond, VA, Paul is responsible for all aspects of fund management and investment-related processes.
Leaving the comforts of a big company with a calcified infrastructure, laser-focused job roles, well-established SOPs, deeper pockets, and excellent job security for the scramble and chaos of a younger company isn’t for everyone.
COVID-19 has created significant challenges for the Venture Capital (VC) market and life science companies seeking funding during the pandemic. While the pandemic has undoubtedly added a new layer of risk to an inherently risky field, the fundamentals for what makes a company attractive to a VC have remained steady.
Ken Malone is a co-founder of Early Charm Ventures, a venture studio founded in 2012 in Baltimore (Charm City) that converts science to business. Early Charm specializes in taking brilliant scientific discoveries made at universities and turning them into companies focused on growth. They don’t chase quick exits. They build companies that create sustainable value.
Olga Maltseva joins Catalio Capital Management LP as Head of Operations in Baltimore
Raising Capital During a Pandemic: Strong Networks and Respected Advocates Remain Critical to Fundraising Efforts Talk to any experienced venture capital investor and they’ll tell you that personal, face-to-face interactions [….]
VCs Cautious of “COVID-19 Contortionists” and Telemedicine “Gold Rush” COVID-19 is fundamentally changing how we live, how we do business, and how we approach and deliver our healthcare. In the [….]
